摘要
背景与目的:体内、外研究均表明,西妥昔单抗可以抑制表达表皮生长因子的人类肿瘤细胞的增殖并诱导其凋亡以及抑制肿瘤血管形成和转移,并已确立其在一线治疗晚期结直肠癌中的地位。本研究观察其在一线治疗晚期结直肠癌的疗效。方法:2007年2月—2007年12月厦门、泉州、漳州三地共五家医院对9例晚期结直肠癌患者应用西妥昔单抗联合化疗进行一线治疗。结果:一线治疗的9例患者中,完全缓解(CR)1例,部分缓解(PR)3例,稳定(SD)3例,进展(PD)2例,一线治疗的有效率(CR+PR)44.4%。疾病控制率(CR+PR+SD)66.6%。结论:晚期结直肠癌一线治疗使用西妥昔单抗联合化疗有较好的疗效,不良反应可耐受。
Background and purpose： In vivo and in vitro studies have confirmed that cetuximab could inhibit the proliferation, induce apoptosis of tumor cells which express epidermal growth factor receptor （EGFR）, and inhibit both tumor metastasis and angiogenesis. Its value has been established in the first-line treatment of advanced or metastatic colorectal cancer （CRC） recently. In our study, we explored the efficiency of cetuximab in the .firstline treatment of the patients with advanced or metastatic colorectal cancer（CRC）. Methods.- From February 2007 to December 2007, a total of 9 CRC patients came from Xiamen, Quanzhou and Zhangzhou, were treated with cetuximab plus chemotherapy regimen. Results. Of the 9 cases, the overall response rate（CR＋PR） was 44.4% with 1 complete response（CR）, 3 partial response（PR）, 3 stable disease（SD） and 2 progressive disease （PD）. Disease control rate（CR＋PR＋SD） was 66.6%. Conclusion： Cetuximab plus chemotherapy in first-line treatment of advanced CRC proved to be active and tolerable.
出处
《中国癌症杂志》
CAS
CSCD
2008年第9期704-706,共3页
China Oncology
关键词
结直肠癌
西妥昔单抗
一线治疗
colorectal cancer
cetuximab
first-line treatment
